{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.20","value":"22.19"},{"groupId":"OG001","spread":"34.51","value":"28.73"}]}],"title":"Post-Surgery (1-7 days)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.74","value":"14.24"},{"groupId":"OG001","spread":"28.78","value":"20.18"}]}],"title":"Post-Surgery (1-14 days)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.21","value":"12.82"},{"groupId":"OG001","spread":"25.01","value":"15.85"}]}],"title":"Post-Surgery (1-21 days)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.67","value":"9.88"},{"groupId":"OG001","spread":"22.54","value":"13.46"}]}],"title":"Post-Surgery (1-26 days)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.32","value":"8.76"},{"groupId":"OG001","spread":"20.91","value":"12.14"}]}],"title":"Post-Surgery (1-35 days)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.32","value":"6.64"},{"groupId":"OG001","spread":"16.96","value":"11.02"}]}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Narcotic consumption was assessed in daily total morphine equivalents averaged over a week. This outcome was assessed at 7 days after surgery and 35 days after surgery.\n\nMorphine equivalent dose (MED) is the amount of opioid prescription drugs a patient is taking per day. MED is the sum of the total morphine milligram equivalents (MMEs), a common unit for assessing milligrams of morphine, dose per day.\n\nThe Post-Surgery (1-7 days) time point is MED from 1 to 7 days after surgery. The Post-Surgery (1-14 days) time point is MED from 1 to 14 days after surgery. The Post-Surgery (1-26 days) time point is MED from 1 to 26 days after surgery. The Post-Surgery (1-35 days) time point is MED from 1 to 35 days after surgery. The End of Treatment time point is MED from 1 to 146 days after surgery.","dispersionType":"Standard Deviation","groups":[{"description":"Patients received celecoxib PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.\n\nCelecoxib: Given PO or via feeding tube\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Celecoxib Arm"},{"description":"Patients received placebo PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.\n\nPlacebo: Given PO or via feeding tube\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG001","title":"Placebo Arm"}],"paramType":"MEAN","populationDescription":"One participant on the Celecoxib Arm was not evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"Post-Surgery (1-7 days) up to 7 days, Post-Surgery (1-14 days) up to 14 days, Post-Surgery (1-26 days) up to 26 days, Post-Surgery (1-35 days) up to 35 days, and End of Treatment up to 146 days.","title":"Assessment of Overall Pain Control and Management for Patients on Celecoxib Compared to Placebo.","type":"SECONDARY","unitOfMeasure":"MME/day"}